Climb Bio, Inc.

Biotechnology • Healthcare • Wellesley Hills, MA, United States • CLYM (NGM)

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target - Investing.com

Investing.com • Dec 30

Climb Bio Stock 7-Day Winning Spree: Stock Climbs 169% - Trefis

Trefis • Dec 17

Climb Bio Enters Exchange Agreement with RA Capital - TipRanks

TipRanks • Dec 11

H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks - Finviz

Finviz • Dec 31

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Yahoo Finance

Yahoo Finance • Dec 28

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Climb Bio, Inc. had layoffs?

No layoff events have been recorded for Climb Bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Climb Bio, Inc. have?

Climb Bio, Inc. has approximately 17 employees.

What industry is Climb Bio, Inc. in?

Climb Bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Climb Bio, Inc. a publicly traded company?

Yes, Climb Bio, Inc. is publicly traded under the ticker symbol CLYM on the NGM. The company has a market capitalization of approximately $0.33 billion.

Where is Climb Bio, Inc. headquartered?

Climb Bio, Inc. is headquartered in Wellesley Hills, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.